Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Dyne Therapeutics, Inc. (DYN : NSDQ)

• Company Description    Dyne Therapeutics Inc. is a muscle disease company focused on advancing innovative life-transforming therapeutics for patients with genetically driven diseases. The company's proprietary platform includes FORCE(TM). Dyne Therapeutics Inc. is based in WALTHAM, Mass. Number of Employees: 191

• Price / Volume Information    Yesterday's Closing Price: $19.56 Daily Weekly Monthly 20 Day Moving Average: 2,949,705 shares Shares Outstanding: 142.82 (millions) Market Capitalization: $2,793.65 (millions) Beta: 1.32 52 Week High: $26.18 52 Week Low: $6.36 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -5.28% -5.12% 12 Week 33.24% 31.09% Year To Date 0.00% 0.00%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 1560 TRAPELO ROAD - WALTHAM,MA 02451 USA ph: 781-786-8230 fax: 781-786-8866 ir@dyne-tx.com http://www.dyne-tx.com

• General Corporate Information    Officers John G. Cox - President; Chief Executive Officer and Director Jason Rhodes - Director and Chairman of the Board Richard Scalzo - Senior Vice President; Head of Finance and Adminis Ed Hurwitz - Director Carlo Incerti - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 26818M108 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 09/01/25 Next Expected EPS Date: 02/26/26 Share - Related Items Shares Outstanding: 142.82 Most Recent Split Date: (:1) Beta: 1.32 Market Capitalization: $2,793.65 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.79 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-3.11 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 9.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 02/26/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 4.02 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 20.83% vs. Previous Quarter: 21.65% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 12/31/25 - - 09/30/25 - -66.17 06/30/25 - -64.12 ROA 12/31/25 - - 09/30/25 - -56.35 06/30/25 - -56.75 Current Ratio 12/31/25 - - 09/30/25 - 13.47 06/30/25 - 16.83 Quick Ratio 12/31/25 - - 09/30/25 - 13.47 06/30/25 - 16.83 Operating Margin 12/31/25 - - 09/30/25 - - 06/30/25 - - Net Margin 12/31/25 - - 09/30/25 - - 06/30/25 - - Pre-Tax Margin 12/31/25 - - 09/30/25 - - 06/30/25 - - Book Value 12/31/25 - - 09/30/25 - 4.86 06/30/25 - 4.02 Inventory Turnover 12/31/25 - - 09/30/25 - - 06/30/25 - - Debt-to-Equity 12/31/25 - - 09/30/25 - 0.14 06/30/25 - 0.17 Debt-to-Capital 12/31/25 - - 09/30/25 - 12.53 06/30/25 - 14.74

Powered by Zacks Investment Research ©